Last reviewed · How we verify
SQ tree SLIT-tablet
At a glance
| Generic name | SQ tree SLIT-tablet |
|---|---|
| Sponsor | ALK-Abelló A/S |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis (PHASE3)
- A Dose-response Evaluation of the SQ Tree SLIT-tablet Using an Environmental Exposure Chamber (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SQ tree SLIT-tablet CI brief — competitive landscape report
- SQ tree SLIT-tablet updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI